Vincamine

The demand for diagnosis and treatment of senile cognitive impairment and cerebrovascular diseases continues to rise. As a natural alkaloid cerebrovascular dilator, vincamine has become a common clinical choice due to its unique mechanism of action. It acts on cerebral vascular smooth muscle with high selectivity, increases the content of cyclic adenosine monophosphate in vascular smooth muscle by inhibiting phosphodiesterase activity, dilates cerebral small vessels in the lesion area without affecting the systemic circulation, improves cerebral oxygen and blood supply and energy metabolism, meanwhile enhances the tolerance of neurons to hypoxia and regulates the level of neurotransmitters in the brain. It is clinically mainly used for the treatment of psychological and behavioral disorders in the aging period, acute cerebrovascular disease and post-traumatic brain syndrome, ischemic retinal diseases, cochleovestibular diseases, etc., covering patients with middle-aged and elderly cerebrovascular diseases, people with cognitive function decline, and patient groups with related ischemic diseases in the ophthalmology and otolaryngology departments.

At present, the global market size of vincamine has exceeded 1.2 billion yuan, with an annual compound growth rate maintained at around 5.8%. The growth momentum mainly comes from the increase in the prevalence of cognitive impairment and cerebrovascular diseases caused by the intensification of global population aging, as well as the improvement of the coverage of chronic disease management for cerebrovascular diseases by primary medical institutions. In the domestic market, generic drug enterprises occupy a dominant position. More than 20 enterprises have obtained marketing approval for vincamine-related preparations, and the production of APIs is mainly concentrated in characteristic phytomedicine extraction enterprises in Shandong, Jiangsu and other regions, with relatively stable overall supply.

The original research enterprise of vincamine is Solvay Pharmaceuticals of France, with the original research trade name "Cetal". Its core compound patent expired globally in the 1980s. The main dosage forms approved for the original research include sustained-release capsules (specification: 30mg) and injections (specification: 2ml:10mg). Among them, the 30mg sustained-release capsules have been included in the China Listed Drug Catalogue as reference preparations, and are also included in the FDA Reference Preparation Catalogue. Up to now, there are 11 vincamine API registration records on the API registration platform of China Center for Drug Evaluation (CDE), 8 of which are in the status of "A" (already used in marketed preparations). Multiple preparation varieties such as vincamine sustained-release capsules and vincamine for injection have been approved for marketing in China. (Data as of October 2024, please refer to the official website of CDE for the latest information)

In response to the quality control needs of vincamine API, CATO can provide a full set of impurity reference standards for this API. Most of the products support spot supply. Spot orders placed before 16:00 can be shipped on the same day. All products comply with multiple regulatory standards such as Chinese Pharmacopoeia and FDA, which can fully meet the full-process quality research needs of pharmaceutical enterprises from API R&D to marketing application.